Effect of chronic liver disease on clinical outcome in renal allograft recipients.
Durlik
M
M
Transplantation Institute, Warsaw Medical School, Poland.
Gaciong
Z
Z
Soluch
L
L
Rowińska
D
D
Rancewicz
Z
Z
Kozłowska-Boszko
B
B
Lewandowski
Z
Z
Rowiński
W
W
Szmidt
J
J
Lao
M
M
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D001803:Blood Transfusion; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006085:Graft Survival; D006509:Hepatitis B / Q000453:epidemiology* / Q000473:pathology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000453:epidemiology* / Q000473:pathology; D018937:Hepatitis C Antibodies / Q000097:blood; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology; D008099:Liver / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications; D015995:Prevalence; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D008775:Methylprednisolone